The European research-based pharmaceutical industry's commitment to tackling the coronavirus pandemic

EFPIA is the voice of the research-based pharmaceutical industry in Europe. As an industry #WeWontRest in fighting the COVID-19 pandemic.

Our first thoughts are with all those affected by the coronavirus pandemic. We are committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak.

Our aims in this time of public health crisis are to:

- Ensure the safe supply of medicines to the patients that need them
- Research and develop new vaccines, diagnostics and treatments for use in the fight against COVID-19
- **Partner and support organisations on the ground to fight against COVID-19**

WE ARE DOING THIS BY:

Rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.

Bringing together the best scientists from industry and academia through the Innovative Medicines Initiative to accelerate the development of new diagnostics and treatments.

Establishing a direct link between manufacturers and EMA & Heads of Medicines Agencies to provide constant information about stock, manufacturing capacity and market tensions in order to anticipate and pro-actively address any potential disruptions or shortages

Continuously monitoring our supply chains and working to ensure the supply of medicines to the patients that need them.

Working with the European Institutions, Member States, public health partners, the research community, healthcare professionals and other partners to fight the spread of COVID-19

Launching clinical development of potential vaccines against the corona virus.

Sharing the learnings from clinical trials in real time with governments and other companies to advance the development of new therapies.

Expanding our manufacturing capabilities and sharing available capacity to ramp up production once a successful medicine or vaccine is developed.

Coordinating with governments and diagnostic partners to increase COVID-19 testing capability and capacity.

Providing financial support and in-kind donations to organisations at the front line across Europe and beyond.

Working with governments and health systems to ensure that when new treatments and vaccines are approved they are available and affordable.

Protecting our workforce and the communities where we live and work, having employees working from home whenever possible.





